These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12370053)

  • 1. Liposomes for intravenous drug targeting: design and applications.
    Metselaar JM; Mastrobattista E; Storm G
    Mini Rev Med Chem; 2002 Aug; 2(4):319-29. PubMed ID: 12370053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes.
    Lu J; Jeon E; Lee BS; Onyuksel H; Wang ZJ
    J Control Release; 2006 Feb; 110(3):505-13. PubMed ID: 16356575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
    McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
    Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome size and charge optimization for intraarterial delivery to gliomas.
    Joshi S; Cooke JR; Chan DK; Ellis JA; Hossain SS; Singh-Moon RP; Wang M; Bigio IJ; Bruce JN; Straubinger RM
    Drug Deliv Transl Res; 2016 Jun; 6(3):225-33. PubMed ID: 27091339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels.
    Krasnici S; Werner A; Eichhorn ME; Schmitt-Sody M; Pahernik SA; Sauer B; Schulze B; Teifel M; Michaelis U; Naujoks K; Dellian M
    Int J Cancer; 2003 Jul; 105(4):561-7. PubMed ID: 12712451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virosomes: evolution of the liposome as a targeted drug delivery system.
    Kaneda Y
    Adv Drug Deliv Rev; 2000 Sep; 43(2-3):197-205. PubMed ID: 10967226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A.
    Rensen PC; Gras JC; Lindfors EK; van Dijk KW; Jukema JW; van Berkel TJ; Biessen EA
    Curr Drug Discov Technol; 2006 Jun; 3(2):135-44. PubMed ID: 16925521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.
    Ishida O; Maruyama K; Tanahashi H; Iwatsuru M; Sasaki K; Eriguchi M; Yanagie H
    Pharm Res; 2001 Jul; 18(7):1042-8. PubMed ID: 11496943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends and developments in liposome drug delivery systems.
    Lian T; Ho RJ
    J Pharm Sci; 2001 Jun; 90(6):667-80. PubMed ID: 11357170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of risperidone liposomes for brain targeting through intranasal route.
    Narayan R; Singh M; Ranjan O; Nayak Y; Garg S; Shavi GV; Nayak UY
    Life Sci; 2016 Oct; 163():38-45. PubMed ID: 27593571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of liposomal formulations for cell targeting.
    Nogueira E; Gomes AC; Preto A; Cavaco-Paulo A
    Colloids Surf B Biointerfaces; 2015 Dec; 136():514-26. PubMed ID: 26454541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microfluidic synthesis of multifunctional liposomes for tumour targeting.
    Ran R; Middelberg APJ; Zhao CX
    Colloids Surf B Biointerfaces; 2016 Dec; 148():402-410. PubMed ID: 27639490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes.
    Qu B; Li X; Guan M; Li X; Hai L; Wu Y
    Eur J Med Chem; 2014 Jan; 72():110-8. PubMed ID: 24361523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.
    Audouy SA; de Leij LF; Hoekstra D; Molema G
    Pharm Res; 2002 Nov; 19(11):1599-605. PubMed ID: 12458664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of liposome characteristics and dose on the pharmacokinetics of liposomes coated with poly(amino acid)s.
    Romberg B; Oussoren C; Snel CJ; Hennink WE; Storm G
    Pharm Res; 2007 Dec; 24(12):2394-401. PubMed ID: 17674159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal drug formulations in the treatment of rheumatoid arthritis.
    van den Hoven JM; Van Tomme SR; Metselaar JM; Nuijen B; Beijnen JH; Storm G
    Mol Pharm; 2011 Aug; 8(4):1002-15. PubMed ID: 21634436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration.
    Romberg B; Oussoren C; Snel CJ; Carstens MG; Hennink WE; Storm G
    Biochim Biophys Acta; 2007 Mar; 1768(3):737-43. PubMed ID: 17223070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody.
    Emfietzoglou D; Kostarelos K; Papakostas A; Yang WH; Ballangrud A; Song H; Sgouros G
    J Nucl Med; 2005 Jan; 46(1):89-97. PubMed ID: 15632038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.